Catalog No.: PC-22626Not For Human Use, Lab Use Only.
Glecirasib (JAB-21822) is a highly selective, covalent oral KRAS G12C inhibitor with IC50 of 1.6 nM (SOS1-mediated guanine nucleotide exchange, GDP- KRAS G12C) and IC50 of 7.3 nM in Phospho-ERK inhibition assay in NCI-H358 cells.
Glecirasib (JAB-21822) is a highly selective, covalent oral KRAS G12C inhibitor with IC50 of 1.6 nM (SOS1-mediated guanine nucleotide exchange, GDP- KRAS G12C) and IC50 of 7.3 nM in Phospho-ERK inhibition assay in NCI-H358 cells.
Glecirasib (JAB-21822) potently inhibits cell viability in NCI-H358 cells with IC50 of 23 nM.
Glecirasib (JAB-21822) inhibits mutant KRAS-driven signaling by binding to the GDP-bound oncoprotein and preventing activation of KRAS upon stimulation of upstream signaling factors.
